These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19958394)

  • 41. Comparison of the 6-minute walk test with established parameters for assessment of cardiopulmonary capacity in adults with complex congenital cardiac disease.
    Niedeggen A; Skobel E; Haager P; Lepper W; Mühler E; Franke A
    Cardiol Young; 2005 Aug; 15(4):385-90. PubMed ID: 16014186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease.
    Coghlan JG; Pope J; Denton CP
    Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S27-34. PubMed ID: 20375662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term recovery of exercise ability after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
    Matsuda H; Ogino H; Minatoya K; Sasaki H; Nakanishi N; Kyotani S; Kobayashi J; Yagihara T; Kitamura S
    Ann Thorac Surg; 2006 Oct; 82(4):1338-43; discussion 1343. PubMed ID: 16996930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic sclerosis - continuing progress in developing clinical measures of response.
    Furst D; Khanna D; Matucci-Cerinic M; Clements P; Steen V; Pope J; Merkel P; Foeldvari I; Seibold J; Pittrow D; Polisson R; Strand V
    J Rheumatol; 2007 May; 34(5):1194-200. PubMed ID: 17477486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
    Lonn E
    Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension.
    Andreassen AK; Wergeland R; Simonsen S; Geiran O; Guevara C; Ueland T
    Am J Cardiol; 2006 Aug; 98(4):525-9. PubMed ID: 16893710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.
    Leuchte HH; Holzapfel M; Baumgartner RA; Ding I; Neurohr C; Vogeser M; Kolbe T; Schwaiblmair M; Behr J
    J Am Coll Cardiol; 2004 Mar; 43(5):764-70. PubMed ID: 14998614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of pulmonary vasoreactivity in children with pulmonary hypertension.
    Limsuwan A; Khowsathit P
    Curr Opin Pediatr; 2009 Oct; 21(5):594-9. PubMed ID: 19617831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension.
    Shah SJ; Thenappan T; Rich S; Sur J; Archer SL; Gomberg-Maitland M
    Circ Heart Fail; 2009 Jul; 2(4):278-86. PubMed ID: 19808350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.
    Hopkins WE; Ochoa LL; Richardson GW; Trulock EP
    J Heart Lung Transplant; 1996 Jan; 15(1 Pt 1):100-5. PubMed ID: 8820089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Diagnosis, course and prognosis of pulmonary arterial hypertension].
    Pornin M; Morin D; Guize L
    Ann Cardiol Angeiol (Paris); 1994 Oct; 43(8):479-85. PubMed ID: 7825953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Value of hemodynamic exploration under exercise in chronic bronchitis].
    Quiret JC; Bens JL; Duboisset M; Lesbre JP; Bernasconi P
    Arch Mal Coeur Vaiss; 1975 Sep; 68(9):977-84. PubMed ID: 813599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exercise testing in children with primary pulmonary hypertension.
    Garofano RP; Barst RJ
    Pediatr Cardiol; 1999; 20(1):61-4; discussion 65. PubMed ID: 9861081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives.
    Hoeper MM; Oudiz RJ; Peacock A; Tapson VF; Haworth SG; Frost AE; Torbicki A
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):48S-55S. PubMed ID: 15194178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The effect of Lomir (isradipine) on the tolerance for physical loading and on the gas exchange indices of patients with primary pulmonary hypertension].
    Chazova IE; Belenkov IuN; Mareev VIu; Floria VG; Sinitsyn VE; Nakonechnikov SN
    Ter Arkh; 1994; 66(9):54-7. PubMed ID: 7992215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of exercise testing in the management of pulmonary arterial hypertension.
    Oudiz RJ
    Semin Respir Crit Care Med; 2005 Aug; 26(4):379-84. PubMed ID: 16121314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarkers in pulmonary hypertension.
    Warwick G; Thomas PS; Yates DH
    Eur Respir J; 2008 Aug; 32(2):503-12. PubMed ID: 18669790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiopulmonary exercise testing in the assessment of pulmonary hypertension.
    Arena R; Guazzi M; Myers J; Grinnen D; Forman DE; Lavie CJ
    Expert Rev Respir Med; 2011 Apr; 5(2):281-93. PubMed ID: 21510737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulmonary hypertension trials: how can we do better?
    Hill NS; Roberts K; Preston I
    Expert Rev Respir Med; 2015 Oct; 9(5):551-8. PubMed ID: 26290120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.